Hoth Therapeutics (NASDAQ:HOTH) Issues Earnings Results

Hoth Therapeutics (NASDAQ:HOTH) announced its quarterly earnings results on Wednesday. The company reported ($0.30) EPS for the quarter, Zacks reports.

Hoth Therapeutics Stock Performance

Shares of NASDAQ:HOTH traded up $0.01 on Friday, hitting $1.19. 128,387 shares of the company were exchanged, compared to its average volume of 3,227,985. The company’s 50 day moving average price is $1.53 and its two-hundred day moving average price is $1.29. The firm has a market capitalization of $15.78 million, a price-to-earnings ratio of -1.12 and a beta of 0.63. Hoth Therapeutics has a one year low of $0.66 and a one year high of $3.80.

Hedge Funds Weigh In On Hoth Therapeutics

An institutional investor recently raised its position in Hoth Therapeutics stock. Geode Capital Management LLC raised its position in Hoth Therapeutics, Inc. (NASDAQ:HOTH) by 8.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 122,575 shares of the company’s stock after acquiring an additional 9,071 shares during the period. Geode Capital Management LLC owned about 0.93% of Hoth Therapeutics worth $143,000 as of its most recent SEC filing. Institutional investors own 7.08% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $5.00 price objective on shares of Hoth Therapeutics in a report on Monday, August 18th. Wall Street Zen cut shares of Hoth Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Hoth Therapeutics in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $4.50.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.